A new study reveals Canadians experience significantly longer wait times for access to new medications compared to their counterparts in Europe and the United States. The findings, detailed in a report by Kristina Acri, chair of the Department of Economics and Business at Colorado College, and Lauren Asaad of Canada’s Fraser Institute, highlight potential challenges within the country's healthcare system.

According to the study’s summary, Canadians wait an average of 65 weeks longer than Europeans to receive new medicines. The disparity is even more pronounced when compared to the United States, where Canadians face an average wait of 90 weeks. These extended delays can impact patient health and access to potentially life-saving treatments.

The study doesn't explicitly attribute these delays to any single factor, but the context of Canada's government-dominated healthcare system is implicitly raised through the report’s broader implications. The Fraser Institute, a Canadian public policy think-tank, has previously published research examining healthcare access and efficiency within Canada. Acri's expertise in economics and Asaad's affiliation with the Fraser Institute lend credibility to the study's analysis and findings. The study's focus is on quantifying the difference in wait times, providing a data-driven perspective on a critical aspect of healthcare accessibility in Canada.